Evidence map›Paper›PMID 34762222›Full record

ArticleJournal of thrombosis and thrombolysis2022

Development and validation of an analytical method for the determination of direct oral anticoagulants (DOAC) and the direct thrombin-inhibitor argatroban by HPLC-MS/MS.

Lea Brückner, Jan Beyer-Westendorf, Oliver Tiebel, Jörg Pietsch

Abstract read
In one paragraph

Article in Journal of thrombosis and thrombolysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lea BrücknerHochschule Für Technik Und Wirtschaft, Friedrich-List-Platz 1, 01069, Dresden, Germany.
Jan Beyer-WestendorfDivision Hematology, Department of Medicine 1, Universitätsklinikum Dresden, Fetscherstr. 74, 01307, Dresden, Germany.ORCID http://orcid.org/0000-0002-6983-9993
Oliver TiebelInstitute of Clinical Chemistry and Laboratory Medicine, Universitätsklinikum Dresden, Fetscherstr. 74, 01307, Dresden, Germany.
Jörg PietschInstitute of Legal Medicine, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany. Joerg.Pietsch@tu-dresden.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since direct oral anticoagulants (DOAC) are administered frequently to an elderly, co-morbid population, medical emergencies including trauma, acute bleeding or organ failure are not uncommon. In these situations, the type, dosage or the time of last intake of anticoagulants is often unknown and single substance analysis by functional tests is only possible if the substance contained in the sample is known. A reliable and validated toxicology screen of DOAC and argatroban would be helpful inform not only attending physicians in the emergency department but also law enforcement and courts of justice. After precipitation with acetone, HPLC separation was achieved on a Phenomenex Luna Pentafluorophenyl Colum using acetonitrile-water (90:10, v/v) as mobile phase system. Detection was performed using a 3200 Q Trap mass spectrometer (AB Sciex). For analysis MRM Scans (MS/MS) with positive ionization were chosen. The method was validated for blank serum as the matrix of choice. Limits of detection are between 0.5 and 1.0 ng/mL, limits of quantification are between 1.9 and 3.6 ng/mL and recoveries are above 60%. The applicability of the method was demonstrated by the determination of DOAC in body fluids from forensic cases and in therapeutic drug monitoring. The rapid simultaneous detection and quantification of apixaban, argatroban, dabigatran etexilate, dabigatran, edoxaban and rivaroxaban in body fluids by HPLC-MS/MS closes an important gap in emergency toxicology.

Indexed as

AntithrombinsThrombinAdministration, OralAgedAnticoagulantsArginineChromatography, High Pressure LiquidDabigatranHumansPipecolic AcidsPyridonesRivaroxabanSulfonamidesTandem Mass SpectrometryAnticoagulantsAntithrombinsargatrobanArginineDabigatranPipecolic AcidsPyridonesRivaroxabanSulfonamidesThrombinArgatrobanDirect oral anticoagulantsDirect thrombin-inhibitorDOACHigh performance liquid chromatography—tandem mass-spectrometry (HPLC–MS/MS)

Identifiers

PMID34762222
PMCPMC9148290

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.